Abstract
To the Editor: Cell therapy is emerging as a realistic treatment for type 1 diabetes, on the basis of the prolonged success of intraportal islet transplantation in selected patients.1 Key improvements include the development of alternative implantation sites and new tools for in vivo detection of transplanted cells. In the absence of reliable beta-cell markers, previous clinical attempts to visualize transplanted islets have relied on magnetic resonance imaging2 and positron-emission tomography.3 However, these techniques necessitate the in vitro manipulation of islets and are limited by the short half-life of available labeling agents. Glucagon-like peptide 1 (GLP-1)–receptor scanning has been successfully . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
